CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
87.30
-0.93 (-1.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close88.23
Open87.97
Bid0.00 x 1000
Ask0.00 x 1200
Day's Range87.25 - 88.79
52 Week Range58.59 - 106.67
Volume6,702,077
Avg. Volume9,387,114
Market Cap61.131B
Beta (3Y Monthly)1.44
PE Ratio (TTM)22.73
EPS (TTM)3.84
Earnings DateJan 23, 2019 - Jan 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est102.78
Trade prices are not sourced from all markets
  • TheStreet.com9 hours ago

    Jim Cramer: There's a Ton More Deals in the Pipe

    The acquirers are snapping up targets like mad because the targets have seen their stocks collapse from the Great Bear Market of 2018, also known as the Powell-Pow Bear market, because Jay Powell hit stocks Pow! right in the kisser when he set out his automaton rate increase plan at the beginning of October. The creation of this new financial technology payments company is a huge win for First Data shareholders who owned a $17 stock just yesterday. David Faber on CNBC reported that these two companies had been talking for months.

  • Regeneron (REGN) Sails Steady on Label Expansion of Drugs
    Zacks11 hours ago

    Regeneron (REGN) Sails Steady on Label Expansion of Drugs

    Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.

  • Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming
    Investor's Business Daily15 hours ago

    Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming

    Takeda Pharmaceutical wrapped its $62 billion acquisition of Shire last week. CEO Christophe Weber predicts it won't be the last merger in the hot biopharma sector.

  • Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
    Investor's Business Dailyyesterday

    Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter

    Incyte stock launched Tuesday after an analyst suggested its portfolio of cancer treatments could net the biotech stock an acquisition offer. Biotech deals have been rampant this month.

  • Here's How The Government Shutdown Will Affect These Medical Stocks
    Investor's Business Dailyyesterday

    Here's How The Government Shutdown Will Affect These Medical Stocks

    The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.

  • GuruFocus.comyesterday

    David Rolfe Comments on Celgene

    Celgene (NASDAQ:CELG) challenged us for the quarter, and quite frankly, the full year, as management failed to deliver on their promising pipeline of drugs. In review of the year, Celgene came out swinging with their $9 billion acquisition of Juno in January 2018, which brought into the Celgene portfolio of drugs JCAR017 (now liso-cell, for B-cell non-Hodgkin lymphoma) and JCARH125 (BCMA for multiple myeloma). While the deal made sense as it was in Celgene's area of expertise (blood cancer) and would allow for a path to diversify the revenue base away from their blockbuster drug Revlimid, it brings the question if the purchase price was too rich or if any of their assumptions in future revenue and/or time to market for these acquired drugs were too aggressive.

  • TheStreet.com2 days ago

    Takeda Pharmaceutical CEO Talks Big Pharma Trends

    Big pharmaceutical companies have begun 2019 with a bang. $62 billion buyout of Shire Plc have signaled the acquisition appetite in the space is strong. To understand the pipeline still ahead and the rationale for such massive mergers and acquisitions, TheStreet joined Takeda Pharmaceutical's CEO Christophe Weber on the New York Stock Exchange, shortly after his company rang the opening bell to celebrate the Japanese giant's U.S. listing.

  • Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
    Zacks2 days ago

    Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer

    Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Celgene Corp.

    # Celgene Corp ### NASDAQ/NGS:CELG View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for CELG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold CELG had net inflows of $12.87 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe
    Investor's Business Daily2 days ago

    Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe

    House Democrats launched an investigation into a dozen pharmaceutical companies on Monday, focusing on drug prices and prompting shares to topple. AstraZeneca and Novo Nordisk fell hard.

  • Celgene (CELG) Stock Moves -0.45%: What You Should Know
    Zacks2 days ago

    Celgene (CELG) Stock Moves -0.45%: What You Should Know

    Celgene (CELG) closed the most recent trading day at $87.01, moving -0.45% from the previous trading session.

  • Reuters2 days ago

    U.S. lawmaker launches investigation into pharma drug pricing

    A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Representative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement.

  • GuruFocus.com2 days ago

    David Rolfe's Wedgewood Partners 4th Quarter Client Letter

    Top fourth quarter performance detractors include Apple, Facebook, Qualcomm, Visa, and Celgene. Top fourth quarter performance contributors include Alphabet, PayPal, Core Laboratories, Fastenal, and Ulta Beauty. Top 2018 performance detractors include Celgene, Facebook, Schlumberger, Kraft Heinz and Charles Schwab.

  • CNBC3 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • CNBC3 days ago

    Biotech is in the midst of major breakout, but one technician says buyer beware

    Biotech's having a huge run, but one technician is warning about the sector.

  • PR Newswire3 days ago

    INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Merger

    NEW YORK , Jan. 13, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • 3 Top Biotech Stocks to Buy in January
    Motley Fool4 days ago

    3 Top Biotech Stocks to Buy in January

    Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.

  • Morningstar5 days ago

    Morningstar Runs the Numbers

    We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Jan. 11.

  • Barrons.com5 days ago

    Why Bristol-Myers Squibb Can Be a Sweet Pill for Investors

    Wall Street has soured on the deal for Celgene, but Bristol-Myers has one of the lowest valuations in the drug sector and could itself become a takeover target

  • Here are the best Dow and S&P stocks so far in 2019
    MarketWatch5 days ago

    Here are the best Dow and S&P stocks so far in 2019

    DEEP DIVE Memories of a brutal fourth-quarter haven't been erased, but investors are breathing a sigh of relief with a reversal in the direction of stocks so far this year. In fact, U.S. stocks have gotten off to their best start in 13 years.

  • 7 Pharmaceutical Stocks That Just Raised Prices This Year
    InvestorPlace5 days ago

    7 Pharmaceutical Stocks That Just Raised Prices This Year

    Given the meltdown we've seen across the entire market over the past 16 weeks, many investors may be overlooking company-specific and industry-specific news. One of those pieces of news? That a swath of pharmaceutical stocks are raising their prices in the new year. Pharmaceutical stocks and biotech companies are interesting plays in any market, partly due to their secular business nature. Meaning that, recession or boom, consumers need treatment. Whether it's as large as open heart surgery or small as a Tylenol, we pay for healthcare when we need it. For as secular as the group can be though, it has been under tremendous volatility lately. With that in mind, almost 40 companies started of 2019 with a series of prices hikes. The average raise was roughly 6.3%. So who were these companies and how do we trade their stocks? InvestorPlace - Stock Market News, Stock Advice & Trading Tips * InvestorPlace Roundup: The Hottest Stocks in the Market Today Let's look at a few of those pharmaceutical stocks. ### Allergan (AGN) Allergan (NYSE:AGN) is known for its vast drug and treatment portfolio. However, at the turn of the year, Allergan raised prices on 51 of its products. That's just over half of its portfolio. Of those 51 products, 27 of them saw an increase of 9.5%. The rest were bumped by 4.9%. All that said, Allergan makes the case that it's not a money-hungry cash grab. Rather, the company says it should not see any net gains as a result of the price hikes because it's providing higher rebates and discounts to its distributors. Allergan may say that, but investors sure wish it would help. Analysts expect sales to fall 1.7% this year and another 1.6% next year. On the earnings front, expectations call for a 90-basis-point gain this fiscal year before a 0.7% decline in 2019. Essentially, estimates call for flat earnings growth overall from fiscal 2017 through 2019. That's likely one factor for why the stock has gone from $195 in October to roughly $125 at its December lows. As AGN approaches the $145 to $150 level now, look to see if and where resistance comes into play. There's downtrend resistance at play, as well as the gap-fill up near $145. It would be encouraging to see the $140-ish level hold as support, but that doesn't leave much wiggle room for Allergan. ### Bristol-Myers (BMY) No one is talking about recent dividend payout from Bristol-Myers Squibb (NYSE:BMY), nor are they talking about its recent price increases. The company raised prices on its cancer drugs Opdivo and Yervoy by 1.5%, while lifting prices by 6% on its chemotherapy treatment Sprycel and its autoimmune disease drug Orencia. However, most investors are talking about the company's $74 billion cash and stock acquisition of Celgene (NASDAQ:CELG). BMY was hammered on the news at first, but rebounded by about 4% on Friday once investors were able to digest the news. Management expects the deal to close in the third quarter of 2019. Creating over $2 billion in synergies and boosting growth, BMY management is hoping the acquisition makes its stock more attractive to investors. At just 12 times forward earnings with 8.5% sales growth and 28% earnings growth this year, BMY already looks reasonable. Throw in its 3.5% dividend yield and its even more attractive. * Morgan Stanley: 7 Risky Stocks to Sell Now On the charts, it's clear that dips down to the upper $40s have been viewed as buying opportunities by investors over the last four years. ### Eli Lilly (LLY) Eli Lilly (NYSE:LLY) isn't exempt when it comes to drug price increases, as it raises prices for Jardiance, a treatment for type 2 diabetes, by 6%. Unlike some of its peers, Eli Lilly has been on absolute fire. Shares are up 35% year-over-year and about 60% from its February lows. Despite the rally, LLY still pays out a 2.2% dividend yield and trades at a somewhat reasonable 20.6 times this year's earnings. Despite the big breakout rally in July, LLY has modest growth expectations. Analysts expect 6.8% and 4% sales growth this year and next year, respectively. Further, estimates call for 30.4% earnings growth this year and 6.5% growth in 2019. Fueling the breakout during the summer? A strong second-quarter result and potential IPO for one of its businesses. However, some may feel that LLY stock has rallied too far, too fast and that it's no longer a worthy buy. According to the charts, that may be the case if LLY is unable to push higher and take out its recent highs near $120. If it can break that level, the rally can continue. If not, look to see if uptrend support holds (blue line). Should it fail, LLY could be heading for a retest of its 200-day moving average. ### Pfizer (PFE) Pfizer (NYSE:PFE) delayed various price hikes in 2018, but pushed through its increases at the start of the year. Not many companies have been as open as Allergan about confirming its specific price hikes, but Pfizer may need them to keep pace in 2019. That is to say, PFE was one of the best-performing stocks in the Dow Jones last year. After consolidating between $30 and $36 for most of the last five years, shares finally broke out around the same time Eli Lilly did. In fact, their charts look quite similar too. After a big breakout six months ago, PFE is having trouble pushing higher. Should it fail to get through the 50-day and short-term uptrend support (blue line) gives way, a test of the 200-day moving average could be in the cards. Should it fail as support, a test of $38 is likely in store. Above the 50-day and a rally to $46 is possible. * 10 Stocks You Can Set and Forget (Even In This Market) Investors not worried about the charts will key in on Pfizer's 3.4% dividend yield and its valuation of 14 times this year's earnings. Although remember that 2018's 13.2% earnings growth is expected to slow to just 2.7% in 2019. ### Biogen (BIIB) Biogen (NASDAQ:BIIB) was also on the list of price increases for 2019. The company increased prices on its multiple sclerosis medications Tecfidera by 6%, Plegridy by 2% and Tysabri by 3.5%. Like other biotech stocks, Biogen has been volatile and struggling. Nowhere is this more evident than on the charts. Shares went from $370 in February to $250 in a matter of months, then hit nearly $400 per share in late July. Now near $330, BIIB bulls are near a make-or-break point. The stock has put in a series of lower highs (blue circles) since that big rally in July. Currently, both the 50-day and the 200-day moving averages rest at about $313. Investors who believe BIIB is attractive -- trading at about 12 times forward earnings with expectations to grow sales and earnings 2.5% and 8.5% in 2019, respectively -- will want to see it hold above these two marks. Should it fail, Biogen could quickly head to the bottom of its recent channel, somewhere in the $270 range. On the plus side though, if shares push higher and can close above $340, BIIB may be starting a new uptrend. ### Teva (TEVA) While Warren Buffett's Berkshire Hathaway (NYSE:BRK.B, NYSE:BRK.A) holds a $750 million stake in Teva Pharmaceuticals (NYSE:TEVA), it's far from his largest holding. Big or small, the Oracle has to be disappointed with the stock's recent action, falling from $24 in November to less than $15 at its lows last month. Now up over $17, bulls are hoping Teva stock can continue higher. Will it? Like the others on this list, Teva also raised prices on some of its drugs this year, although the specifics are not well known. So far the name has done well this year, though granted, were just a few sessions into 2019. In any regard, Teva is bumping into the backside of prior downtrend support (blue line). Should this level act as resistance, bulls will want $16.75 to act as support. If not, the recent lows are in play. Over resistance and the $19 to $20 level is on the table. * The 7 Best Stocks in the Entrepreneur Index While the stock trades at less than 7 times this year's earnings, keep in mind that growth has been tough. Sales are forecast to fall 15.8% this year, while analysts expect earnings to contract by 27%. In 2019, the slowdown decelerates, but analysts are still calling for a 4.8% reduction in revenue and a 3% fall in earnings. ### Insys Therapeutics (INSY) Though it is much smaller than most of the names on this list, Insys Therapeutics (NASDAQ:INSY) is joining them in raising prices -- in this case, on its pain-relief medication Subsys. INSY has a market cap of just $350 million. The move is probably necessary, given that sales are forecast to fall about 40.5% this year and another 5% in 2019. It doesn't help that INSY doesn't turn a profit, although its lack of debt is encouraging. Given the selloff we've seen in the stock market since the start of Q4 2018, it's no surprise that investors have cut INSY very little slack. Shares came into Q4 near $10, but are now clinging to the $4.25 level. To say it's been a rough ride would be an understatement. However, INSY is holding up over the $4 level and is right at downtrend resistance. A push higher to $5 would be encouraging, even if this level acts as resistance on its first attempt. But a break below $4 -- especially in the near-term -- would be worrisome and puts the lows back on the table. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 7 Pharmaceutical Stocks That Just Raised Prices This Year appeared first on InvestorPlace.

  • CNBC6 days ago

    Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference

    Two new deals to start the year and positive trial presentations at the J.P. Morgan Health Care conference have breathed new life into some of last year's biggest stock losers.

  • InvestorPlace6 days ago

    The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock

    So far, 2019 is starting off with a bang in the pharmaceutical industry. Last week, we learned that Bristol-Myers Squibb (NYSE:BMY) is buying out beleaguered Celgene (NASDAQ:CELG) in a behemoth $74 billion takeover. Eli Lilly (NYSE:LLY) followed that up with a large deal of its own, announcing an $8 billion offer for Loxo Oncology (NASDAQ:LOXO). Whether the purchase helps Eli Lilly stock in the long term is another question altogether. While it may seem small compared to the blockbuster Celgene deal, $8 billion is still a major announcement. Don't forget Gilead Science's (NASDAQ:GILD) deal to buy the revolutionary Hep-C cure company Pharmasset for $11 billion in 2011. Within a couple years, GILD stock quintupled as the Pharmasset drugs lifted Gilead's profitability to the stratosphere. Needless to say, Loxo, if it delivers in similar fashion, could fundamentally reshape Eli Lilly's future for many years to come. That's especially as Eli Lilly has some patent expirations of its own to consider and really could use a big new product launch or two. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks at Risk of the Global Smartphone Slowdown ### Loxo: A Steep Price Could Hamper Eli Lilly Stock It's no secret that biotech stocks got crushed in the 2018 correction. The SPDR Biotech ETF (NYSEARCA:XBI) dropped as much as 35% within three months. That meant that companies with strong balance sheets had the ability to go discount shopping. Bristol-Myers was first to take a big swing with the Celgene deal. However, Eli Lilly's move will also be a game-changer. Not only did Eli Lilly pay $8 billion for Loxo, they also paid a huge premium. LOXO stock previously traded as high as $188/share. Due to the biotech correction it was trading around $140 prior to Eli Lilly's offer. As such, you'd think something like $200/share (above Loxo's all-time high) would be enough to close the deal. Instead, Eli Lilly offered a whopping $235/share. Now, to be fair to Eli Lilly, Loxo did enjoy a positive development in that interim period; they managed to get FDA approval for their leading pipeline drug candidate. Though, that approval was widely expected. Regardless, Eli Lilly is paying heavily for a company that is just at the beginning of the commercialization process for their drug candidates. ### Loxo and Eli Lilly Stock Loxo has taken a different path from most companies in oncology. Instead of targeting its drugs for specific types of cancer, such as lung or prostate, Loxo targets genetic mutations. These genetic mutations appear to lead to cancers across a variety of different body parts. Loxo's first approved drug targets NTRK gene fusions. This is a rare condition which occurs in roughly 0.2% of the population. Loxo estimates that there are a few thousand eligible patients with NTRK fusions in the U.S. at this time. Thus, with a nearly $400,000/year price tag for the drug, it may take longer than expected for Loxo's product to become a huge commercial seller. The Chief Business Officer for Loxo, Jake Naarden, stated last year that: "We expect the initial launch to be challenging, though we remain optimistic about the longer-term trajectory. One of the truisms you often hear about new drug launches is that the first few quarters determine the commercial fate of the drug. Given the penetration of tumor genomic testing today, we do not believe that the first few quarters of this launch will inform very much." He makes an important point. Most oncology patients are not prescribed genomic testing today. Additionally, some genomic tests do not include the NTRK fusion. As a result, many potentially eligible patients may not know that Loxo has a beneficial therapy for their condition. This, however, highlights one big advantage to the Eli Lilly purchase. Eli Lilly has far more connections and influence within the medical community. It has the budget and reach to ensure that more cancer patients test their genomes and are aware of potential novel solutions. It's likely that Eli Lilly's purchase will bring Loxo's first drug far more attention and quicker clinical uptake. Loxo also brings its promising Loxo-292 therapy which is still in clinical trails. ### Eli Lilly Stock Takeaway One point in favor of the deal is that Eli Lilly has a strong balance sheet and can pay for Loxo with cash. Heading into the deal, Eli Lilly had $9 billion in cash against $13 billion in total debt. The Loxo purchase will consume almost all of the company's existing cash reserves, but still leave it in a reasonably sound fiscal position. After adjusting for one-time expenses, Eli Lilly will earn in the ballpark of $4.5 billion dollars for 2018. That means that it's net debt load is not especially problematic. On a debt/EBITDA basis, it comes in around 1.5x, which is quite conservative. From an earnings basis, the Loxo deal will consume just under two full years of Eli Lilly's ongoing net income. Given the limited size of Loxo's market, at least at first, Eli Lilly won't earn back its $8 billion purchase price in the near-term. But the potential is still great. Eli Lilly is buying a drug platform with a rather novel approach to treating cancer. If the company is able to commercialize other Loxo drugs that are earlier along in clinical trials, the deal could end up being a big win for Eli Lilly stock. At this point, Eli Lilly stock may be a bit overvalued. It's still trading at 20x forward earnings. That's quite aggressive for a pharma company, as patent expirations tend to keep PE ratios rather low. And Eli Lilly stock is up 35% over the past year which is a stark contrast to struggles elsewhere in the health care space. As for the Loxo deal in particular, it could pay off big, but for now, a wait and see approach seems most prudent. At the time of this writing, Ian Bezek owned GILD stock. You can reach him on Twitter at @irbezek. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock appeared first on InvestorPlace.

  • Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer
    Zacks6 days ago

    Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer

    Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.

  • Dealmaking surge confirms the stock market got far too ch...
    CNBC Videos8 hours ago

    Dealmaking surge confirms the stock market got far too ch...

    Jim Cramer explains why there's been more merger and acquisition activity in recent months and says it's "just getting started."